Myeloid-derived suppressor cells in atherosclerosis

This project will explore how MDSCs contribute to the immune landscape of atherosclerosis and influence the balance between inflammation and resolution within plaques. We will characterise how their abundance and activity relate to disease severity, and investigate the factors that control their generation, recruitment, and suppressive capacity. By comparing findings from human disease with insights from experimental models, we aim to uncover mechanisms that could be leveraged to restore or enhance MDSC function. The ultimate goal is to determine whether strengthening these natural immune-regulatory pathways could represent a new approach to stabilising plaques and reducing the risk of major cardiovascular events.

To investigate the role of myeloid-derived suppressor cells (MDSCs) in atherosclerosis and assess their potential as targets for reducing vascular inflammation and improving cardiovascular outcomes.

Atherosclerosis, the underlying cause of heart attacks, stroke, and peripheral artery disease, is increasingly recognised as an immune-driven disease. While inflammatory immune cells are well known to drive plaque progression and instability, other immune populations, such as MDSCs, can suppress excessive inflammation and maintain immune balance. MDSCs are well-studied in cancer but remain poorly understood in cardiovascular disease, and their potential protective role in atherosclerosis is largely unexplored. Understanding how MDSCs are regulated, and why their function may become impaired in disease, could open new therapeutic avenues.